Aberrant promoter methylation of multiple genes in non-small cell lung cancers

Cancer Research

Volumn 61, Issue 1, 2001, Pages 249-255

  Zöchbauer Müller, Sabine ^a   Fong, Kwun M ^c   Virmani, Arvind K ^a   Geradts, Joseph ^d   Gazdar, Adi F ^a,b   Minna, John D ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GLUTATHIONE TRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN KINASE; PROTEIN P16; RETINOIC ACID RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER SURGERY; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENES, P16; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROTEINS; RECEPTORS, RETINOIC ACID; RISK FACTORS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0035132145     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines
2. DNA methylation affects the formation of active chromatin
3. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p 16/CDKN2/MTS1 in human cancers
4. Alterations in DNA methylation: A fundamental aspect of neoplasia
5. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
6. Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor β gene in human colon carcinoma cells
7. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia
8. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies
9. DNA methylation of retinoic acid receptor β in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine
10. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
11. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers
12. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia
13. INK4α methylation and p53 mutational status
14. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers
15. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
16. INK4α is an early event in lung cancer and a potential biomarker for early diagnosis
17. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3
18. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth
19. Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells
20. Lung tumors in mice expressing an antisense RARβ2 transgene
21. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas
22. Correlation of loss of heterozygosity at 11p with tumour progression and survival in non-small cell lung cancer
23. Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer
24. Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer
25. Microsatellite instability and other molecular abnormalities in non-small cell lung cancer
26. MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer
27. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations
28. INK4α, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers
29. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
30. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small ceil lung cancer, and loci clustering
31. p53 protein accumulates frequently in early bronchial neoplasia
32. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung
33. Molecular damage in the bronchial epithelium of current and former smokers
34. High frequency of retinoic acid receptor β abnormalities in human lung cancer
35. Human lung cancer cell lines exhibit resistance to retinoic acid treatment
36. Suppression of retinoic acid receptor β in non-small-cell lung cancer in vivo: Implications for lung cancer development
37. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression
38. Progress in understanding the molecular pathogenesis of human lung cancer